Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
Year : 2010  |  Volume : 6  |  Issue : 4  |  Page : 588

Irinotecan as a maintenance therapy for hepatoblastoma: A comment

Wiwanitkit House, Bang Khae, Bangkok, Thailand

Date of Web Publication24-Feb-2011

Correspondence Address:
V Wiwanitkit
Wiwanitkit House, Bang Khae, Bangkok 10160
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0973-1482.77092

Rights and Permissions

How to cite this article:
Wiwanitkit V. Irinotecan as a maintenance therapy for hepatoblastoma: A comment. J Can Res Ther 2010;6:588

How to cite this URL:
Wiwanitkit V. Irinotecan as a maintenance therapy for hepatoblastoma: A comment. J Can Res Ther [serial online] 2010 [cited 2022 May 21];6:588. Available from: https://www.cancerjournal.net/text.asp?2010/6/4/588/77092


Several novel therapeutic approaches for the treatment of children with hepatoblastoma are currently available. Irinotecan is a new drug proposed for its effectiveness in high-risk patients with hepatoblastoma. [1] Qayed et al. found that irinotecan can be used as an effective maintenance therapy for hepatoblastoma. [2] However, hepatoblastoma is rare and clinical trials on irinotecan have usually included only a few subjects. Hence, it remains uncertain whether irinotecan is the optimal treatment for hepatoblastoma. Side effects of irinotecan should also be of concern. An important serious side effect of irinotecan is chemotherapy-induced diarrhea that can be a significant problem for patients. [3] For the studies with few subjects, it might be difficult to assess the magnitude of this side effect of irinotecan. Another important side effect is the genotoxicity. It should be noted that increased vitamin A, C and E of cells exposed to irinotecan is related to increased degree of genotoxicity. [4] Hence, vitamin status should be addressed in using irinotecan for the treatment of hepatoblastoma.

 > References Top

1.Katzenstein HM, Rigsby C, Shaw PH, Mitchell TL, Haut PR, Kletzel M. Novel therapeutic approaches in the treatment of children with hepatoblastoma. J Pediatr Hematol Oncol 2002;24:751-5.  Back to cited text no. 1
2.Qayed M, Powell C, Morgan ER, Haugen M, Katzenstein HM. Irinotecan as maintenance therapy in high-risk hepatoblastoma. Pediatr Blood Cancer. 2010.  Back to cited text no. 2
3.Richardson G, Dobish R. Chemotherapy induced diarrhea. J Oncol Pharm Pract 2007;13:181-98.  Back to cited text no. 3
4.Kontek R, Drozda R, Sliwinski M, Grzegorczyk K. Genotoxicity of irinotecan and its modulation by vitamins A, C and E in human lymphocytes from healthy individuals and cancer patients. Toxicol in Vitrol 2009.  Back to cited text no. 4


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article

 Article Access Statistics
    PDF Downloaded226    
    Comments [Add]    

Recommend this journal